NEW YORK, Dec. 4 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) today announced that Jonathan Lewis, M.D., Ph.D., has stepped down from his position as a director of the Company, effective December 2, 2008. Dr. Lewis advised the Company that his decision to leave the Delcath board is a result of additional commitments to new leadership positions.
Dr. Harold Koplewicz, Chairman of the Board of Directors of Delcath Systems, commented, "We all thank Jon for his dedicated service to Delcath and wish him the best in his future professional pursuits."
About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.
This release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the current belief of management. These statements relate to, among oth
|SOURCE Delcath Systems, Inc.|
Copyright©2008 PR Newswire.
All rights reserved